Patents by Inventor Athan BAILLET

Athan BAILLET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR ESTIMATING THE EFFECTIVENESS OF TREATMENT WITH AN ANTI-CD20 AGENT IN A PATIENT WITH RHEUMATOID ARTHRITIS AND HAVING HAD AN INADEQUATE RESPONSE TO AT LEAST ONE BIOTHERAPY
    Publication number: 20220137045
    Abstract: The present invention relates to a method for estimating the effectiveness of treatment with an anti-CD20 agent in a patient with rheumatoid arthritis and who has had an inadequate response to at least one prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said agent is a treatment that will engender a beneficial response for said patient. The present invention also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data, the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of said treatment in said patient.
    Type: Application
    Filed: April 29, 2020
    Publication date: May 5, 2022
    Applicant: SINNOVIAL
    Inventors: Philippe GAUDIN, Athan BAILLET, Anaïs COURTIER, Minh-Vu-Chuong NGUYEN, Jacques-Eric GOTTENBERG
  • METHOD FOR ESTIMATING THE EFFECTIVENESS OF A TREATMENT BY AN ANTI-TNF ALPHA AGENT IN A PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS AND HAVING AN INADEQUATE RESPONSE TO AT LEAST ONE BIOTHERAPY
    Publication number: 20220057382
    Abstract: The present invention relates to a method for estimating the effectiveness of treatment with an anti-TNF? agent in a patient with rheumatoid arthritis and who has had an inadequate response to at least one prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said agent is a treatment that will engender a beneficial response for said patient. The present invention also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data, the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of the treatment in said patient.
    Type: Application
    Filed: December 18, 2019
    Publication date: February 24, 2022
    Applicant: SINNOVIAL
    Inventors: Philippe GAUDIN, Athan BAILLET, Anaïs COURTIER, Minh-Vu-Chuong NGUYEN, Lisa GUIGUE, Jacques-Eric GOTTENBERG
  • METHOD FOR ESTIMATING THE EFFECTIVENESS AGAINST RHEUMATOID ARTHRITIS OF A T-LYMPHOCYTE CO-STIMULATION MODULATOR AGENT
    Publication number: 20200241007
    Abstract: The disclosure relates to a method for estimating the effectiveness of treatment with a T-lymphocyte cell co-stimulation modulator agent in a patient with rheumatoid arthritis and who has had an inadequate response to prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said modulator agent is a treatment that will engender a beneficial response for said patient. The disclosure also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data concerning the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of said treatment in said patient.
    Type: Application
    Filed: October 18, 2018
    Publication date: July 30, 2020
    Applicant: SINNOVIAL
    Inventors: Anaïs COURTIER, Minh Vu Chuong NGUYEN, Athan BAILLET, Philippe GAUDIN, Jacques-Eric GOTTENBERG